NASDAQ
21.07.25 | 19:36
0,479 US-Dollar
-4,81 % -0,024
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | ALX Oncology berichtet über Ergebnisse der Jahreshauptversammlung | 4 | Investing.com Deutsch | ||
| 12.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | H.C. Wainwright maintains ALX Oncology stock Buy rating | 3 | Investing.com | ||
| 20.05. | ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event | 143 | GlobeNewswire (Europe) | - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the... ► Artikel lesen | |
| 13.05. | ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 | 3 | GlobeNewswire (USA) | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.58 misses by $0.10 | 2 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | 316 | GlobeNewswire (Europe) | Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | What's Next: ALX Oncology Holdings' Earnings Preview | 1 | Benzinga.com | ||
| 02.05. | ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | 3 | GlobeNewswire (USA) | ||
| 25.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials | 1 | FierceBiotech | ||
| 25.04. | ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma | 186 | GlobeNewswire (Europe) | - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated... ► Artikel lesen | |
| 25.04. | ALX Oncology falls on mid-stage trial setback for lead asset | 1 | Seeking Alpha | ||
| 25.04. | ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints | 201 | GlobeNewswire (Europe) | In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains... ► Artikel lesen | |
| 08.04. | ALX Oncology's ALX2004 gains FDA IND clearance to treat solid tumours | 1 | Pharmaceutical Business Review | ||
| 07.04. | ALX Oncology gets FDA clearance to begin trial of ALX2004 | 3 | Seeking Alpha | ||
| 07.04. | ALX Oncology bringt neues Krebsmedikament in Phase-1-Studien | 2 | Investing.com Deutsch | ||
| 07.04. | ALX Oncology advances new cancer drug into Phase 1 trials | 2 | Investing.com |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 26,840 | -1,70 % | Tesla und Moderna: Das sind die Short-Kandidaten von JPMorgan | © Foto: DALL*ETesla und Moderna gehören zu den Aktien, bei denen JPMorgan im zweiten Halbjahr 2025 zu Short-Positionen rät.Zum Start ins zweite Halbjahr ließ Pedro Martins Junior, Co-Leiter der US-Aktienanalyse... ► Artikel lesen | |
| NOVAVAX | 6,000 | -0,46 % | UNGLAUBLICHE Sondermeldung bei Novavax Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| CRISPR THERAPEUTICS | 57,00 | +1,79 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| INOVIO PHARMACEUTICALS | 1,230 | +1,65 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,990 | +5,88 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,414 | +1,47 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| EDITAS MEDICINE | 2,560 | +7,97 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 11,590 | -4,33 % | Sarepta Therapeutics-Aktie +35%: Ist das die Wende? | Die Kursentwicklung der Sarepta Therapeutics -Aktie trieb Anlegern in jüngster Vergangenheit nur die Tränen in die Augen. In den letzten zwölf Monaten lösten sich fast -90% des Börsenwerts des Biotech-Unternehmens... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 48,850 | -0,91 % | BioMarin: Wolfe Research bestätigt Outperform-Rating trotz neuer Konkurrenz im PKU-Markt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,281 | +9,11 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| EXELIXIS | 38,240 | -0,08 % | Truist Securities raises Exelixis stock price target to $56 on positive outlook | ||
| VAXART | 0,349 | +8,72 % | OTC Markets Group Welcomes Vaxart, Inc. to OTCQX | NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 112,10 | -1,32 % | NBIX: Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) shared new results from a one-year clinical study at the Endocrine Society's 2025 Annual Meeting in San Francisco. The study looked... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 48,320 | -0,56 % | Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,024 (-4,81 %) liegt der Kurs bei 0,479 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.